Quarterly ResultApr 30, 2026, 04:10 PM
PCRX Q1 Revenue $177.4M, +5%; Repurchases $50M Shares
AI Summary
Pacira BioSciences reported Q1 2026 total revenue of $177.4 million, a 5% increase year-over-year, driven by growth across its commercial portfolio, including 7% EXPAREL volume growth. GAAP net income decreased to $2.9 million ($0.07 per share) from $4.8 million ($0.10 per share) in Q1 2025. The company also repurchased 2.2 million shares for $50.0 million and reiterated its full-year 2026 financial guidance. Additionally, Pacira completed enrollment in its Phase 3 ZILRETTA study for shoulder osteoarthritis, with topline results expected by year-end.
Key Highlights
- Repurchased 2.2M shares for $50.0M; $100.0M remains on authorization.
- Q1 2026 total revenue $177.4M, up 5% from $168.9M YoY.
- Q1 2026 GAAP net income $2.9M ($0.07/share), down from $4.8M ($0.10/share) YoY.
- EXPAREL net product sales $143.3M, up 5% YoY with 7% volume growth.
- ZILRETTA net product sales $26.8M, up 15% YoY.
- iovera° net product sales $6.2M, up 21% YoY.
- Reiterated 2026 total revenue guidance: $745M to $770M.
- Completed enrollment in Phase 3 ZILRETTA study for shoulder OA.